PR Newswire

PR Newswire
Share

PR Newswire

 •  September 14

Merit Medical Systems, a leading manufacturer of proprietary disposable devices and the exclusive distributor of the Surfacer System in Europe, will be sponsoring the symposium titled The Surfacer Inside-Out Access Catheter System: To Restore and Preserve Access in Chronically Occluded Veins. The symposium will take place on Sunday, September 17th...

PR Newswire

 •  July 6

Centurion has been awarded two Premier group purchasing agreements. In a statement from Centurion: "Centurion's vascular access solutions include CVC Stock™+ Bundles, a new concept in central line insertion trays. The stock tray breaks down into three distinct zones — maximum barrier, catheter insertion, and site protection. Centurion's ability to...

PR Newswire

 •  July 6

The Global Intravenous (IV) Therapy and Vein Access Market Should Reach $29 Billion by 2021 from $21.6 Billion in 2016 at a CAGR of 6.1%, from 2016 to 2021 Growing emphasis on cost-effectiveness and cost-containment at health care facilities along with technological advances have enabled the safe and effective use of IV therapies. This is driving...

PR Newswire

 •  June 30

"Our teams have been working diligently to enroll as many infusion center sites as possible in advance of RADICAVA becoming available in the U.S. to ensure the treatment process is as smooth and convenient as possible for physicians and their patients," said Atsushi Fujimoto, President, MT Pharma America. "These efforts are part of our ongoing...

PR Newswire

 •  June 19

the United States and Canada, announced today that its Board of Directors, with the assistance of legal counsel, has carefully reviewed 22NW Fund, LP's unsolicited proposal and determined that the $2.00 per share proposal is inadequate and that pursuing such a transaction at the present time is not in the best interests of InfuSystem's...

PR Newswire

 •  June 16

HORSHAM, Pa., June 16, 2017 /PRNewswire/ -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the immunotherapy DARZALEX® (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including...

PR Newswire

 •  June 14

New York during MD&M East, the largest annual medical technology conference on the East Coast for the medical manufacturing industry. "It's an honor for ivWatch to be recognized by the MDEA judges for the outstanding design of our device," said Gary P. Warren, ivWatch president and CEO. "IV infiltration is a major problem for the medical community...

PR Newswire

 •  June 5

"The results of our Phase Ia trial with MVT-5873 indicate that we have a fully-human antibody targeting CA19-9 cancers that can be administered at doses with acceptable safety and with a potentially positive impact on disease. CA19-9 is broadly expressed in various cancers including pancreatic, colon, and small cell lung cancer making this antibody...

PR Newswire

 •  June 1

Researchers from Children's Hospital of Philadelphia (CHOP) who conducted the study recommend follow-up investigations to further evaluate the device. The study appeared online ahead of the printed version in the journal Pediatric Emergency Care. "This is the first study to compare a vibrating cold device to topical lidocaine in reducing the pain...

PR Newswire

 •  May 18

AMARILLO, Texas, May 18, 2017 /PRNewswire/ -- Maxor National Pharmacy Services, LLC ("Maxor"), today announced that Vertex Pharmaceuticals Inc. has now included Maxor Specialty, comprised of IV Solutions and Pharmaceutical Specialties ("PSI"), in its specialty pharmacy network. Effectively immediately, patients may now utilize Maxor Specialty for...